Market Overview

Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules

Related PRGO
Benzinga's Top #PreMarket Losers
Markets Gather Some Momentum As Volume Remains Light, Geopolitical Tension Improving
Horizon Inks $660M Reverse Merger With Ireland's Vidara (Fox Business)

Perrigo Company (Nasdaq: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun.

This new product for the U.S. store brand market is bioequivalent to Novartis' Prevacid® 24HR capsules (15 mg) and is indicated for the treatment of frequent heartburn, which occurs two or more days in a week. Sales for Prevacid OTC were approximately $220 million.

Posted-In: News FDA

 

Related Articles (PRGO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters